Eli Lilly (LLY)
(Delayed Data from NYSE)
$762.33 USD
+22.26 (3.01%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $761.75 -0.58 (-0.08%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Eli Lilly and Company has a PEG ratio of 1.68 compared to the Large Cap Pharmaceuticals industry's PEG ratio of 1.24.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LLY 762.33 +22.26(3.01%)
Will LLY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LLY
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
Stock Market News for Aug 1, 2025
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
Eli Lilly (LLY) Declines More Than Market: Some Information for Investors
Other News for LLY
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Eli Lilly (LLY) Stock Rises Amid Coverage Expansion for Weight Loss Drugs
Eli Lilly: The Best Growth Prospects Come At A Price
Eli Lilly (LLY) to Benefit from Proposed Coverage of Weight Loss Drugs by Medicare and Medicaid
Trump Administration Plan Signals Shift Toward Weight-Loss Drug Coverage For Medicare Patients